LMO2 Inhibitors Targeting Protein Interface
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective compounds that can specifically inhibit the activity of the T cell leukemia chromosomal translocation protein, LMO2, which is overexpressed in various cancers, including T cell acute lymphoblastic leukemia, leading to uncontrolled cell proliferation.
Innovation Solution
Development of pharmacologically active compounds that target the LMO2 protein, inhibiting its activity by binding to its interface, thereby modulating its function and reducing its interaction with natural partners, which are used in pharmaceutical compositions for treating cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intracellular antibodies (iDAbs) are used to inhibit LMO2 protein-protein interactions, then high affinity and specificity are achieved, but the molecule size is large and complex
Solution Approach 1:
The patent creates simplified copies of the intracellular antibody binding interface by identifying and synthesizing small molecules that replicate the key interaction features. The Abd technology captures essential binding motifs from the iDAb structure and translates them into drug-like small molecules that maintain affinity and specificity while dramatically reducing molecular complexity
Solution Approach 2:
The patent extracts the critical binding interface elements from the large intracellular antibody structure. By identifying the specific amino acid residues and structural features responsible for LMO2 binding, the invention isolates and reproduces only the essential binding elements in small molecule form, discarding the unnecessary bulk of the antibody structure
2Device complexity
If small molecule surrogates are developed from iDAb templates, then molecular complexity is reduced, but binding affinity and specificity may be compromised
Solution Approach 1:
The patent systematically optimizes small molecule parameters including molecular weight, hydrophobicity, hydrogen bonding capacity, and steric configuration to match the binding requirements of LMO2. By adjusting these physical-chemical parameters, the invention achieves high affinity binding with small molecules that would otherwise be too simple to bind specifically
Solution Approach 2:
The patent concentrates binding energy at specific local sites on the small molecule that correspond to key interaction hotspots on the iDAb binding interface. Rather than attempting uniform interaction across the entire molecule, the design focuses computational and synthetic effort on creating precise local chemical environments that maximize binding affinity at critical contact points
3Adaptability or versatility
If chromosomal translocation proteins are targeted for therapy, then tumour-specific treatment is achieved, but the proteins lack well-defined binding sites
Solution Approach 1:
The patent divides the large, flat protein-protein interaction interface into discrete segments or hotspots. By identifying and targeting specific local regions rather than attempting to bind the entire interface at once, the invention creates multiple small molecule candidates that can be tested and optimized. This segmentation transforms an intractable binding problem into manageable sub-problems
Solution Approach 2:
The patent transitions from attempting to bind the two-dimensional protein surface to creating small molecules with three-dimensional pharmacophores that can access and bind specific geometric features of the interface. By introducing vertical and depth dimensions through molecular design, the invention creates binding modes that are possible only with three-dimensional small molecules rather than flat protein surfaces
Data Source
AI summary
The present invention relates to compounds of Formula (I) that function as LMO2 activity: Formula (I) wherein R1, X1, X2, X3, Q, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which LMO2 activity is implicated.